Specifica
Specifica is a Santa Fe-based, IQVIA-affiliated antibody engineering company that designs and transfers proprietary Generation 3 in vitro antibody libraries, paired with cloud-based AbXtract bioinformatics, to global pharmaceutical and biotechnology partners for therapeutic discovery.
- Company typePrivate
- Founded2016
- HeadquartersSanta Fe, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Specifica does
Specifica, Inc. is a privately held antibody engineering company founded in 2016 and headquartered in Santa Fe, New Mexico, operating as a subsidiary of Q2 Solutions (part of IQVIA). The company builds and transfers Generation 3 in vitro antibody libraries using phage and yeast display, combined with next-generation sequencing quality control, and complements these libraries with AbXtract, a cloud-based bioinformatics module (exclusively embedded in OpenEye's Orion Antibody Discovery Suite) that uses proprietary ML methods to cluster antibody sequences and identify leads from NGS outputs. Libraries are delivered in Fab, scFv, and VHH formats, and Specifica reports that over 80% of output antibodies show no measurable biophysical liabilities, with 60% below 10 nM affinity and 20% subnanomolar.
Specifica monetizes primarily through full platform transfer agreements with global pharmaceutical companies — delivering exclusive libraries, vectors, protocols, and training under multi-year contracts with no downstream royalties — supplemented by in-house antibody discovery services, custom library design, and AI Antibody Data Packages sold to AI/ML model developers. The go-to-market is enterprise field sales targeting pharma R&D and discovery teams; named customers include Sanofi, Servier/Symphogen, Bayer, UCB, AstraZeneca, Incyte, and Scholar Rock. Marketing relies heavily on peer-reviewed publications (Nature Communications, mAbs), conference presence (PEGS, Festival of Biologics), webinars, and an antibody engineering masterclass.
The business is differentiated by patented library construction methods, donor-set exclusivity for each partner, and validated developability metrics; however, scale remains modest (11-50 employees) and no revenue or external funding figures have been disclosed.
Specifica firmographics
Firmographics- Name
- Specifica
- Legal name
- Specifica Inc.
- Website
- https://specifica.bio
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Specifica is a Santa Fe-based, IQVIA-affiliated antibody engineering company that designs and transfers proprietary Generation 3 in vitro antibody libraries, paired with cloud-based AbXtract bioinformatics, to global pharmaceutical and biotechnology partners for therapeutic discovery.
- Ownership category
- akta.pro rank
Specifica industry classification
Industry- Product category
- Antibody Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
Keywords
Where Specifica is headquartered
LocationHeadquarters
- HQ city
- Santa Fe
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Specifica business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Platform Transfer Agreements: Exclusive transfer of Generation 3 antibody libraries, vectors, protocols, and training to pharmaceutical partners. Each library is created from unique donor sets not used for any other library.
- Antibody Discovery Services: In-house antibody discovery campaigns using Specifica's Generation 3 Platform for partners who need additional support.
- Custom Library Design: Collaborative creation of custom antibody display libraries with optimized essential elements according to partner specifications.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Full Platform Transfer |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Specifica product offering
Product offeringCore offering
Specifica designs and delivers Generation 3 in vitro antibody display libraries in Fab, scFv, and VHH formats using phage and yeast display technologies, transferring them to pharmaceutical and biotechnology partners as exclusive assets with vectors, protocols, and training. The company also runs in-house antibody discovery campaigns, provides custom library design services, and offers AbXtract, a cloud-based NGS bioinformatics tool integrated with OpenEye's Orion platform, along with AI Antibody Data Packages for training computational antibody discovery models.
Product overview
Specifica offers a unified antibody discovery ecosystem centered on its Generation 3 Antibody Library Platform as the core technology. The platform combines patented Generation 3 libraries (available in Fab, scFv, and VHH formats) with AbXtract, a cloud-based NGS bioinformatics module exclusively available through the OpenEye Orion platform. Customers access the platform through platform transfer agreements (full technology transfer with exclusive libraries, vectors, protocols, and training) or discovery services (Specifica conducts campaigns on their behalf). AI Antibody Data Packages provide supplementary data for AI/ML training. The ecosystem also includes VHH/single-domain libraries, R&D services, and reagents.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- 60% of antibodies from Generation 3 libraries have affinities below 10nM; 20% subnanomolar; best affinity 13 pM
- +3 more outcomes
Companies that use Specifica
Customer profileNamed customers7 records
Segments2 records
Ideal customer profiles3 records
Specifica technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability4 records
Feature4 records
Specifica partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered major, core and strategic.
- Servier / SymphogenmajorPlatform transfer agreement providing Generation 3 antibody libraries, optimization tools, and computational tools to Symphogen (Servier's antibody center of excellence) for integration into their discovery programs in oncology, neuroscience, and immuno-inflammation.
- SanofimajorComprehensive technology transfer of Specifica's patented Generation 3 Antibody Discovery Platform including Gen 3 libraries, antibody optimization solutions, and integrated discovery tools.
- OpenEye ScientificcoreJoint development partnership to launch Orion Antibody Discovery Suite incorporating Specifica's AbXtract module. OpenEye's cloud-native Orion platform combined with Specifica's bioinformatics tools for antibody discovery analysis.
- IncytestrategicCollaborative development resulting in published research on single donor in vitro library builds and simultaneous affinity maturation with developability enhancement methods.
- UCBmajorDelivery of exclusive antibody library platform to enhance UCB's therapeutic antibody discovery capabilities, providing reliable and rapid source of therapeutic antibody molecules.
- Scholar RockmajorCollaborative design and creation of exclusive antibody display library based on Specifica's Generation 3 platform for therapeutic biologic discovery targeting serious diseases.
- BayermajorTransfer of Generation 3 antibody library suite to Bayer under agreement enabling development of antibody-based therapeutics, following in-house testing by Bayer.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Specifica competitors and assessment
Company assessmentDirect peers
- Adimab: Adimab operates one of the leading proprietary antibody discovery platforms (yeast display-based) used by major pharma for therapeutic antibody leads, directly competing with Specifica's Generation 3 library offering.
- AbCellera Biologics: AbCellera runs a single-cell antibody discovery platform with deep pharma partnerships (including Eli Lilly) and competes directly for antibody discovery platform transfer and partnership engagements.
- Ligand Pharmaceuticals (OmniAb): Ligand's OmniAb business offers transgenic animal and in vitro antibody discovery platforms licensed to pharma and biotech — a directly comparable business model to Specifica's platform transfer approach.
- Trianni: Trianni provides transgenic human antibody mouse platforms and discovery services, serving the same pharma/biotech therapeutic antibody discovery customer base as Specifica.
- Yumab: Yumab offers proprietary antibody library and phage/yeast display-based discovery services to pharma partners, overlapping with Specifica's library and discovery service offerings.
Broad incumbents
- Charles River Laboratories (Distributed Bio): Charles River acquired Distributed Bio and integrates antibody library and discovery capabilities into a broader CRO services portfolio, competing for the same pharma discovery budgets as Specifica.
- GenScript ProBio: GenScript offers antibody discovery services, library construction, and reagents across a broad biologics services portfolio, including custom antibody library offerings overlapping with Specifica's value proposition.
- Bio-Rad Laboratories: Bio-Rad's Life Science segment provides antibody reagents, phage display libraries, and related tools used in antibody discovery and validation, addressing adjacent customer needs to Specifica's offerings.
Emerging players
- Ablexis (AlivaMab Biologics): Ablexis / AlivaMab provides a transgenic human antibody mouse platform for therapeutic discovery, representing an alternative in vivo approach that competes with Specifica's in vitro library platform for the same pharma partnerships.
- Atreca: Atreca applies immune repertoire sequencing and AI to antibody discovery, overlapping with Specifica's NGS-driven selection workflow and target customer base of pharma partners.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Specifica social profiles
Digital presenceSpecifica financial estimates
Financial estimateRevenue estimate
Valuation estimate
Specifica leadership team
Management profileNumber of profiles
Profiles6 records
Specifica funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Specifica M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Specifica
What does Specifica do?
Specifica designs and delivers Generation 3 in vitro antibody display libraries in Fab, scFv, and VHH formats using phage and yeast display technologies, transferring them to pharmaceutical and biotechnology partners as exclusive assets with vectors, protocols, and training. The company also runs in-house antibody discovery campaigns, provides custom library design services, and offers AbXtract, a cloud-based NGS bioinformatics tool integrated with OpenEye's Orion platform, along with AI Antibody Data Packages for training computational antibody discovery models.
Is Specifica a public or private company?
Specifica is a private company. It is classified as corporate owned and is currently operating.
When was Specifica founded?
Specifica was founded in 2016. It employs 11 to 50 people.
Where is Specifica based?
Specifica is headquartered in Santa Fe, United States, in the North America region.
How does Specifica make money?
Three revenue lines are on record. Platform Transfer Agreements are the primary driver. The others are antibody Discovery Services and custom Library Design.
Who are Specifica's main competitors?
Direct peers on record are Adimab, AbCellera Biologics, Ligand Pharmaceuticals (OmniAb), Trianni and Yumab. Broad incumbents are Charles River Laboratories (Distributed Bio), GenScript ProBio and Bio-Rad Laboratories. Emerging players are Ablexis (AlivaMab Biologics) and Atreca.
Does Specifica have an API?
No public API is recorded for Specifica.
What industry is Specifica in?
Specifica's product category is Antibody Discovery Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries). Its NAICS code is 541714 and its SIC code is 8731.